ClinicalTrials.gg
CompletedNCT04542499Updated Apr 4, 2025Results posted

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

A Phase 3 interventional study of Tavapadon and Placebo in Parkinson Disease, sponsored by AbbVie. Completed at 146 sites in 14 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
3rd of 11
507 · median 57
Started
2020
with 2 others
Phase 3
4 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
4 of 11
AbbVie

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 3rd largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 8th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinsonian Disorders
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Disease
  • Movement Disorders
  • Neurodegenerative Diseases
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male and female participants aged 40 to 80 years, inclusive, at the time of signing the form (ICF).
  • Sexually active men or women of must agree to use acceptable (at minimum) or highly effective , or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.
  • Participants who are capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Participants with a diagnosis of PD that is consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria, with bradykinesia and motor asymmetry.
  • Participants with modified Hoehn and Yahr stage 2, 2.5, or 3 in the "on" state.
  • Participants with a good response to levodopa (L- Dopa) in the judgment of the investigator.
  • Participants who return a completed self-reported home diary for motor function status (Hauser diary) during the screening period (after diary training and concordance testing has occurred), with recordings for 2 consecutive days (ie, 2 consecutive 24-hour periods) showing at least 2 and half hours of "off" time on each of the 2 days.
  • Participants who are on a stable dose of L-Dopa for at least 4 weeks prior to screening and are taking a minimum total daily dose of 400 milligram (mg) divided in at least 4 doses per day of standard carbidopa/levodopa or divided in at least 3 doses per day of extended-release carbidopa/levodopa capsules. The carbidopa/levodopa dose and frequency must be maintained for the duration of the trial.
  • Prior and concurrent use of catechol-O-methyltransferase (COMT) inhibitors, monoamine oxidaseB (MAO-B) inhibitors, amantadine, istradefylline or anticholinergic drugs are permitted if the use was initiated greater than (>) 90 days before the baseline visit and the dosage will remain stable for the duration of the trial (ie, no change in the COMT,MAO-B inhibitor, amantadine, istradefylline or anticholinergic dose is permitted during the trial).

Key Exclusion Criteria:

  • Participants with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or post stroke parkinsonism).
  • Participants with a history of nonresponse or insufficient response to L-Dopa at therapeutic dosages.
  • Participants with a history or current diagnosis of a impulse control disorder(Disruptive, Impulse Control, and Conduct Disorder per ).
  • Participants with the presence of or history of brain tumor, hospitalization for severe head trauma, epilepsy (as defined by the International League Against Epilepsy), or seizures.
  • Participants with a history of psychosis or hallucinations within the previous 12 months.
  • Participants who answer "yes" on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent)and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last6 months, OR Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.
  • Participants with substance abuse or dependence disorder, including alcohol, benzodiazepines, and opioids, but excluding nicotine, within the past 6months (180 days).
  • Participants with dementia or cognitive impairment that, in the judgement of the investigator, would exclude the participant from understanding the ICF or participating in the trial.
  • Participants with any condition that could possibly affect drug absorption, including bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).
  • Participants who have a positive result for (HIV) antibodies, surface antigen (HbsAg), or virus (HCV)antibodies at screening.
  • Participants with a history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias that are not controlled with medical and/or surgical intervention; second- or third-degree atrioventricular block; sick sinus syndrome; severe or unstable angina; or congestive heart failure within the last 12months. A recent (less than or equal to [\<=12]months) history of myocardial infarction with secondary arrhythmias is exclusionary regardless of the therapeutic control.
  • Participants with a history of neuroleptic malignant syndrome.
  • Participants who are currently receiving moderate or strong inducers or CYP3A4 inhibitors(except for topical administration).
  • Participants with a positive urine drug screen for illicit drugs are excluded and may not be retested or rescreened. Participants with a positive urine drug screen resulting from use of marijuana (any tetrahydrocannabinol-containing product),prescription, or over-the-counter medications or products that, in the investigator's documented opinion, do not signal a clinical condition that would impact the safety of the participant or interpretation of the trial results may continue evaluation for the trial following consultation and approval by the medical monitor
  • Participants with a (MoCA) score \<26.
  • Participants with clinically significant orthostatic hypotension (eg, syncope).
  • Participants with a 12-lead demonstrating aQTcF interval >450 msec.
  • Participants with moderate or severe renal impairment ( as estimated by Cockcroft-Gault formula \<30 mL/min or on dialysis).
  • Participants with any of the following abnormalities in clinical laboratory tests at the Screening Visit, as assessed by the central laboratory and confirmed by a single repeat measurement, if deemed necessary:
  • (AST) or Alanine Aminotransferase (ALT) >=3 × Upper Limit Normal ().
  • Total >=1.5 × ULN. Participants with a history of Gilbert's syndrome may be eligible provided they have a value \<ULN for direct bilirubin
  • Participants with other abnormal laboratory test results, vital sign results, or ECG findings unless, in the judgment of the investigator, the findings are not medically significant and would not impact the safety of the participants or the interpretation of the trial results.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    Tavapadon

    Participants will receive a tavapadon tablet titrated 5 to 15milligrams (mg) once daily (QD)orally for 27 weeks.

    Drug: Tavapadon

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.

    Drug: Placebo

Interventions

  • Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.

    Also known as: PF-06649751, CVL-751

  • DrugPlacebo

    Participants will receive placebo matching to tavapadon QD orally for 27 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)

    The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at endpoint.

    Time frame: Week 26

Secondary outcomes

  1. Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)

    The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at endpoint.

    Time frame: Week 26

  2. Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)

    The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at different time points.

    Time frame: Week 2, 5, 8, 11, 14, 18, 22, and 26

  3. Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)

    The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at different time points.

    Time frame: Week 2, 5, 8, 11, 14, 18, 22, and 26

  4. Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III Individual Score

    The MDS-UPDRS rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome.

    Time frame: Week 26

07

Results

Posted Mar 25, 2025

Participant flow

In this Phase 3, Double-Blind study, a total of 368 subjects with Parkinson's Disease(PD) were be randomized in a 1:1 ratio to receive Tavapadon (5 mg to 15 mg) or Placebo once daily (QD) for 27 Weeks.

Participant flow — Overall Study
MilestonePlaceboTavapadon
Started255252
Completed206159
Not completed4993
Withdrew: Adverse event2343
Withdrew: Lack of efficacy52
Withdrew: Lost to follow-up34
Withdrew: Failure to meet continuation criteria01
Withdrew: Treatment with prohibited concomitant medications10
Withdrew: Non-compliance with study drug02
Withdrew: Physician decision01
Withdrew: Site terminated by sponsor35
Withdrew: Withdrawal by subject1233
Withdrew: Other22

Outcome measures

PrimaryChange From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)

The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at endpoint.

Time frame:
Week 26
Reported as:
Least squares mean · hours
Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)
hoursPlaceboTavapadon
Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)0.619 ± 0.1881.721 ± 0.207
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 1.103 · 95% CI 0.553 to 1.653
SecondaryChange From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)

The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at endpoint.

Time frame:
Week 26
Reported as:
Least squares mean · hours
Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)
hoursPlaceboTavapadon
Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)-0.933 ± 0.182-1.876 ± 0.200
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0006 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -0.943 · 95% CI -1.475 to -0.410
SecondaryChange From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)

The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at different time points.

Time frame:
Week 2, 5, 8, 11, 14, 18, 22, and 26
Reported as:
Least squares mean · hours
Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)
hoursPlaceboTavapadon
Week 20.535 ± 0.1330.305 ± 0.133
Week 50.516 ± 0.1480.616 ± 0.151
Week 80.470 ± 0.1621.052 ± 0.168
Week 110.705 ± 0.1631.063 ± 0.171
Week 140.584 ± 0.1751.282 ± 0.187
Week 180.623 ± 0.1741.592 ± 0.185
Week 220.870 ± 0.1771.749 ± 0.190
Week 260.619 ± 0.1881.721 ± 0.207
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.2216 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -0.230 · 95% CI -0.600 to 0.139
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.6379 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 0.099 · 95% CI -0.316 to 0.515
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0132 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 0.582 · 95% CI 0.122 to 1.042
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.1299 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 0.358 · 95% CI -0.106 to 0.821
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0068 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 0.698 · 95% CI 0.194 to 1.202
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0002 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 0.969 · 95% CI 0.469 to 1.469
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0008 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 0.879 · 95% CI 0.369 to 1.389
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 1.103 · 95% CI 0.553 to 1.653
SecondaryChange From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)

The Hauser diary assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at different time points.

Time frame:
Week 2, 5, 8, 11, 14, 18, 22, and 26
Reported as:
Least squares mean · hours
Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)
hoursPlaceboTavapadon
Week 2-0.598 ± 0.127-0.490 ± 0.127
Week 5-0.612 ± 0.144-0.849 ± 0.146
Week 8-0.549 ± 0.153-1.367 ± 0.159
Week 11-0.876 ± 0.156-1.629 ± 0.164
Week 14-0.779 ± 0.173-1.682 ± 0.185
Week 18-0.786 ± 0.176-1.810 ± 0.187
Week 22-1.014 ± 0.179-1.993 ± 0.191
Week 26-0.933 ± 0.182-1.876 ± 0.200
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.5471 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 0.108 · 95% CI -0.245 to 0.461
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.2488 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -0.237 · 95% CI -0.640 to 0.166
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0002 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -0.818 · 95% CI -1.252 to -0.384
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0010 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -0.753 · 95% CI -1.199 to -0.307
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0004 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -0.904 · 95% CI -1.403 to -0.405
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -1.024 · 95% CI -1.528 to -0.520
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0002 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -0.979 · 95% CI -1.493 to -0.465
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0006 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -0.943 · 95% CI -1.475 to -0.410
SecondaryChange From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III Individual Score

The MDS-UPDRS rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome.

Time frame:
Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III Individual Score
units on a scalePlaceboTavapadon
Part I0.0 ± 0.270.4 ± 0.30
Part II-0.1 ± 0.35-1.4 ± 0.39
Part III-4.6 ± 0.65-7.0 ± 0.71
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.3265 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: 0.4 · 95% CI -0.4 to 1.2
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0203 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -1.2 · 95% CI -2.2 to -0.2
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0118 (LS Means, SE, difference from placebo, and confidence intervals are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, and treatment by visit interaction and baseline as a covariate.) · Ls mean of difference: -2.4 · 95% CI -4.3 to -0.5

Adverse events

Collected over All-cause mortality were reported from enrollment to the end of study, median time on follow up (median time subjects were followed) was 190 and 189 days for Placebo and Tavapadon, respectively. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 4 weeks after the last dose of study drug; mean duration on study drug was 169.6 and 151.7 days for Placebo and Tavapadon, respectively.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/255 (0%)14/255 (5.5%)90/255 (35.3%)
Tavapadon1/252 (0.4%)17/252 (6.7%)130/252 (51.6%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPlaceboTavapadon
FALLInjury, poisoning and procedural complications0/2553/252
ABDOMINAL PAINGastrointestinal disorders0/2552/252
COVID-19Infections and infestations2/2550/252
ANGINA PECTORISCardiac disorders0/2551/252
CARDIAC FAILURE CHRONICCardiac disorders0/2551/252
GLAUCOMAEye disorders0/2551/252
DIARRHOEAGastrointestinal disorders0/2551/252
BRONCHITIS BACTERIALInfections and infestations0/2551/252
COVID-19 PNEUMONIAInfections and infestations0/2551/252
INFECTIVE ANEURYSMInfections and infestations0/2551/252
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboTavapadon
NAUSEAGastrointestinal disorders11/25536/252
DYSKINESIANervous system disorders4/25525/252
DIZZINESSNervous system disorders8/25518/252
HEADACHENervous system disorders7/25517/252
ORTHOSTATIC HYPOTENSIONVascular disorders3/25515/252
COVID-19Infections and infestations7/25513/252
FALLInjury, poisoning and procedural complications13/25513/252
SOMNOLENCENervous system disorders11/25513/252
HALLUCINATION, VISUALPsychiatric disorders3/25513/252
FATIGUEGeneral disorders11/25510/252

Baseline characteristics

Includes all enrolled subjects that received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboTavapadonTotal
Mean64.1 ± 8.5265.6 ± 8.4264.9 ± 8.49
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTavapadonTotal
Female85101186
Male170151321
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTavapadonTotal
Hispanic or Latino161127
Not Hispanic or Latino232226458
Unknown or Not Reported71522
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTavapadonTotal
American Indian or Alaska Native202
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American426
White245246491
More than one race000
Unknown or Not Reported224
ON Time (hours) Without Troublesome Dyskinesia at Baseline
ON Time (hours) Without Troublesome Dyskinesia at Baseline(hours)PlaceboTavapadonTotal
Mean10.148 ± 2.6379.884 ± 2.56910.016 ± 2.604
OFF Time (hours) at Baseline
OFF Time (hours) at Baseline(hours)PlaceboTavapadonTotal
Mean5.408 ± 2.4845.638 ± 2.2465.523 ± 2.369
Movement Disorder Society - Unified Parkinson's Disease Rating Score at Baseline (Parts I, II, III)
Movement Disorder Society - Unified Parkinson's Disease Rating Score at Baseline (Parts I, II, III)(units on a scale)PlaceboTavapadonTotal
Part I7.5 ± 4.938.0 ± 5.137.7 ± 5.03
Part II12.5 ± 7.0513.3 ± 6.5412.9 ± 6.80
Part III32.4 ± 14.2632.6 ± 14.3432.5 ± 14.29
08

Study locations

146 sites
  • Pheonix, Arizona
    Phoenix, Arizona 85004, United States
  • Little Rock, Arkansas
    Little Rock, Arkansas 72205, United States
  • Fountain Valley, California
    Fountain Valley, California 92708, United States
  • Fresno, California
    Fresno, California 93710, United States
  • Long beach, California
    Long Beach, California 90806, United States
  • Los Angeles, California
    Los Angeles, California 90048, United States
  • Pasadena, California
    Pasadena, California 91105, United States
  • Reseda, California
    Reseda, California 91335, United States
  • Denver, Colorado
    Denver, Colorado 80210, United States
  • Englewood, Colorado
    Englewood, Colorado 80113, United States
  • Adventura, Florida
    Adventura, Florida 33180, United States
  • Atlantis, Florida
    Atlantis, Florida 33462, United States
  • Boca Raton, Florida
    Boca Raton, Florida 33486, United States
  • Boca Raton, Florida
    Boca Raton, Florida 33487, United States
  • Coral Springs, Florida
    Coral Springs, Florida 33067, United States
  • Hallandale Beach, Florida
    Hallandale Beach, Florida 33009, United States
  • Maitland, Florida
    Maitland, Florida 32751, United States
  • Ocala, Florida
    Ocala, Florida 34470, United States
  • Port Charlotte, Florida
    Port Charlotte, Florida 33980, United States
  • Port Orange, Florida
    Port Orange, Florida 32127, United States
  • Tampa, Florida
    Tampa, Florida 33615, United States
  • Winter Park, Florida
    Winter Park, Florida 32792, United States
  • Augusta, Georgia
    Augusta, Georgia 30912, United States
  • Chicago, Illinois
    Chicago, Illinois 60612, United States
  • Elk Grove Village, Illinois
    Elk Grove Village, Illinois 60007, United States
  • Kansas City, Kansas
    Kansas City, Kansas 66160, United States
  • Lexington, Kentucky
    Lexington, Kentucky 40536, United States
  • Scarborough, Maine
    Scarborough, Maine 04074, United States
  • Boston, Massachusettes
    Boston, Massachusetts 02215, United States
  • Boston Neuro Research Center
    North Dartmouth, Massachusetts 02747, United States
  • Farmington Hills, Michigan
    Farmington Hills, Michigan 48334, United States
  • West Bloomfield, Michigan
    West Bloomfield, Michigan 48322, United States
  • Saint Louis, Missouri
    Saint Louis, Missouri 63110, United States
  • Las Vegas, Nevada
    Las Vegas, Nevada 89106, United States
  • Las Vegas, Nevada
    Las Vegas, Nevada 89118, United States
  • Syracuse, New York
    Syracuse, New York 13210, United States
  • Asheville, North Carolina
    Asheville, North Carolina 28806, United States
  • Cincinnati, Ohio
    Cincinnati, Ohio 45212, United States
  • Cleveland, Ohio
    Cleveland, Ohio 44195, United States
  • Columbus, Ohio
    Columbus, Ohio 43221, United States
  • Dayton, Ohio
    Dayton, Ohio 45459, United States
  • Toledo, Ohio
    Toledo, Ohio 43614, United States
  • Memphis, Tennessee
    Memphis, Tennessee 38157, United States
  • Cypress, Texas
    Cypress, Texas 77429, United States
  • Georgetown, Texas
    Georgetown, Texas 78628, United States
  • Houston, Texas
    Houston, Texas 77030, United States
  • Lubbock, Texas
    Lubbock, Texas 79410, United States
  • Round Rock, Texas
    Round Rock, Texas 78681, United States
  • Burlington, Vermont
    Burlington, Vermont 05401, United States
  • Richmond, Virginia
    Richmond, Virginia 23229, United States
  • Richmond, Virginia
    Richmond, Virginia 23233, United States
  • Virginia Beach, Virginia
    Virginia Beach, Virginia 23456, United States
  • Kirkland, Washington
    Kirkland, Washington 98034, United States
  • Spokane, Washington
    Spokane, Washington 99202, United States
  • Clayton VIC
    Clayton, Clayton VIC 3168, Australia
  • Erina, New South Wales
    Erina, New South Wales 2250, Australia
  • Kogarah, New South Wales
    Kogarah, New South Wales 2217, Australia
  • Woolloongabba, Queensland
    Woolloongabba, Queensland 4102, Australia
  • Parkville, Victoria
    Parkville, Victoria 3050, Australia
  • Pleven, Bulgaria
    Pleven, 5800, Bulgaria
  • Pleven
    Pleven, 5800, Bulgaria
  • Multiprofile Hospital, Sofia
    Sofia, 1113, Bulgaria
  • Sofia
    Sofia, 1142, Bulgaria
  • Sofia
    Sofia, 1407, Bulgaria
  • DCC Neoclinic
    Sofia, 1408, Bulgaria
  • Sofia
    Sofia, 1431, Bulgaria
  • Ottawa, Ontario
    Ottawa, Ontario K1Y4E9, Canada
  • Toronto, Ontario
    Toronto, Ontario M5T 2S8, Canada
  • Chocen
    Choceň, Chocen 56501, Czechia
  • Prague, Czech Republic
    Prague, Czech Republic 150 00, Czechia
  • Prague,
    Prague, 100 00, Czechia
  • Prague,
    Prague, 160 00, Czechia
  • Rychnov nad Kněžnou
    Rychnov Nad Kněžnou, 516 01, Czechia
  • Creteil,
    Créteil, Creteil 94010, France
  • Boulevard Pinel, Bron
    Bron, 69500, France
  • Nantes CEDEX 1
    Nantes, 44093, France
  • Nîmes cedex
    Nîmes, 30029, France
  • Strasbourg
    Strasbourg, 67098, France
  • Toulouse Cedex 9
    Toulouse, 31059, France
  • Muenster
    Münster, Muenster 48149, Germany
  • Bad Homburg
    Bad Homburg, 61348, Germany
  • Berlin
    Berlin, 12163, Germany
  • Bochum
    Bochum, 44791, Germany
  • Brandenburg, Germany
    Brandenburg, 14547, Germany
  • Duesseldorf,
    Duesseldorf, 40225, Germany
  • Gera
    Gera, 07551, Germany
  • Haag in Oberbayern
    Haag In Oberbayern, 83527, Germany
  • Muenchen
    Muenchen, 81377, Germany
  • Klinikum rechts der Isar der TU München
    Munich, 81675, Germany
  • Stadtroda
    Stadtroda, 07646, Germany
  • Gyor,
    Győr, Gyor 9024, Hungary
  • Budapest
    Budapest, 1135, Hungary
  • Pecs
    Pécs, 7623, Hungary
  • Szeged
    Szeged, 6725, Hungary
  • Ashkelon
    Ashkelon, 7830406, Israel
  • Haifa
    Haifa, 3109601, Israel
  • Jerusalem
    Jerusalem, 91120, Israel
  • Petah Tiqva
    Petah Tiqva, 49100, Israel
  • Shoham
    Shoham, 6083531, Israel
  • Tel Aviv
    Tel Aviv, 6100000, Israel

Showing the first 100 of 146 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jan 2024, 40 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion. A results delay was requested in Dec 2024.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 40 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2020
First posted
Sep 9, 2020
StartActual
Sep 23, 2020
Primary completionActual
Jan 29, 2024
CompletionActual
Feb 15, 2024
Results delay requested
Dec 13, 2024
Results first posted
Mar 25, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04542499
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Sep 23, 2020
Primary completion
Jan 29, 2024
Completion
Feb 15, 2024
Results posted
Mar 25, 2025
Last update
Apr 4, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion